Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
ccPixs.com / Flickr Creative Commons
The Wall Street Journal has a smart and important piece about a murky side of high drug prices. It looks at the charities that help patients pay their out-of-pocket costs for prescription drugs — but also get hundreds of million dollars a year from drug companies. And in helping the patients cover their costs, the charities help drug companies boost their sales.
The new plot twist: Federal prosecutors are investigating the charities that help Medicare patients, and now donations to charities that help pay for prostate cancer drugs have slowed down — and sales of prostate cancer drugs have plummeted.
Why it matters: There's been a lot of debate about whether financial assistance programs help keep drug costs high, because there's no consequence to the drug companies as long as patients can keep buying them.